Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche

Executive Summary

Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS

You may also be interested in...



Emend Medicare coverage

CMS is developing a national coverage determination for Merck's anti-emetic Emend and will accept public comment until Aug. 6, agency says July 6. CMS "internally generated a national coverage determination to determine if aprepitant is full replacement for other covered treatment(s) for chemotherapy-induced emesis," agency said. "If aprepitant is determined to be full replacement, CMS will then describe the circumstances where it is reasonable and necessary for Medicare beneficiaries." CMS' targeted completion date for the NCD is April 1, 2005...

Emend Risk Program To Ensure Prescribers Understand Approved Indication

Merck's risk management program for Emend will emphasize the anti-emetic's approved indication to deter prescribing for non-approved indications

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel